Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Pulmonary Obstructive Disorder (COPD): Update Bulletin #1 [July 2018]

Product Code:
596201008
Publication Date:
July 2018
Format:
PDF
Price:
£910

This edition presents key opinion leader (KOL) views on recent developments in the Chronic Obstructive Pulmonary Disease (COPD) market. Topics covered include: Verona Pharma presenting data for its first-in-class, inhaled, dual phosphodiesterase-3/phosphodiesterase-4 (PDE3/4) inhibitor RPL554; AstraZeneca and its subsidiary MedImmune announcing top line results from Phase III trials of its anti-interleukin (IL)-5 monoclonal antibody (mAb) Fasenra (benralizumab); Circassia presenting Phase IV data for its long-acting muscarinic antagonist (LAMA) Tudorza Pressair (aclidinium inhalation powder), and Phase III data for its combined LAMA/long-acting beta agonist (LABA) Duaklir Pressair (aclidinium/formoterol inhalation powder).

Business Questions:

• How effective is the PDE3/4 inhibitor RPL554 in terms of producing additional bronchodilation for patients with COPD when used on top of Spiriva?
• How do KOLs view the safety profile of nebulised RPL554 and will further trials be required to confirm this assessment?
• If RPL554 also demonstrates anti-inflammatory activity, how could this affect its use within the COPD treatment paradigm?
• What are the reasons underlying Fasenra’s failure to meet the primary endpoints in the Phase III GALATHEA and TERRANOVA trials?
• Do KOLs think that better patient selection could have increased Fasenra’s chances of reducing exacerbations in patients with moderate to very severe COPD?
• Can KOLs identify any patient sub-groups in which Fasenra might prove beneficial as a COPD therapy?
• What conclusions can be drawn from the results of the ASCENT study about the safety and efficacy of Tudorza Pressair as a treatment for COPD?
• What do the AMPLIFY data reveal regarding the bronchodilatory effect of the combined LAMA/LABA therapy Duaklir Pressair?
• If Duaklir Pressair is approved in the US, what must Circassia do in order to maximise its chances of competing successfully in an already crowded market?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved